BRIDGEBIO PHARMA, INC.

BRIDGEBIO PHARMA, INC. is a Corporation in WILMINGTON, United States with 10 ISIN-identified securities mapped to its LEI, which is how regulators tie a traded instrument to the issuer behind it.

The LEI has been on record for 7 years, since 6 Jun 2019. That puts it right on the median for United States, where half of all LEIs date from before 2019.

The next annual re-validation is due 11 Jul 2027, 239 days from now.

The record has not changed since we began archiving it on 6 Jul 2026. Any future change to name, status, address, ownership or renewal date will be captured here, because GLEIF publishes only the current state and superseded values are otherwise lost.

The LEI is issued and maintained by Herausgebergemeinschaft Wertpapier-Mitteilungen Keppler, Lehmann GmbH & Co. KG, one of the Local Operating Units accredited by GLEIF.

Beyond the LEI, 10 ISINs are mapped to this entity in the GLEIF cross-reference files.

No direct accounting-consolidating parent is reported, because the parent is not publicly disclosed. GLEIF requires this to be stated explicitly rather than left blank, so the absence is itself a data point.

No ultimate accounting-consolidating parent is reported, because the parent is not publicly disclosed. GLEIF requires this to be stated explicitly rather than left blank, so the absence is itself a data point.

The LEI registration is issued, and the entity status (active) records whether the legal entity itself still exists. The two are independent: an LEI can lapse while the company trades on, and it can stay issued after the company has been dissolved.